Anbio Biotechnology (NASDAQ:NNNN) Shares Up 4.4% - Still a Buy?

Key Points

• Shares of Anbio Biotechnology (NASDAQ:NNNN) rose to about $27.30, up 4.4% on Tuesday, but trading volume was only 8,882 shares—around 84% below the average session volume.
• Weiss Ratings downgraded the stock from a "hold (c-)" to a "sell (d+)", and MarketBeat shows the stock's consensus analyst rating is currently Sell.
• In the most recent quarter the company reported EPS $0.04 on $2.29 million in revenue, and the shares are trading above their 50‑day moving average of $23.88.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) shot up 4.4% during trading on Tuesday . The stock traded as high as $27.40 and last traded at $27.3040. 8,882 shares changed hands during mid-day trading, a decline of 84% from the average session volume of 54,838 shares. The stock had previously closed at $26.15.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut shares of Anbio Biotechnology from a "hold (c-)" rating to a "sell (d+)" rating in a research report on Wednesday, April 1st. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Anbio Biotechnology currently has an average rating of "Sell".

Anbio Biotechnology Trading Up 1.3%

The business has a 50-day moving average price of $23.88.

Anbio Biotechnology (NASDAQ:NNNN - Get Free Report) last announced its earnings results on Tuesday, December 30th. The company reported $0.04 earnings per share (EPS) for the quarter. The business had revenue of $2.29 million for the quarter.

About Anbio Biotechnology

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.